Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · IEX Real-Time Price · USD
5.19
0.00 (0.00%)
At close: May 28, 2024, 12:53 PM
4.970
-0.220 (-4.24%)
After-hours: May 28, 2024, 4:00 PM EDT
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 198.65% from the current stock price of 5.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APRE stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +285.36% | May 14, 2024 |
| Wedbush | Wedbush | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +111.95% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +285.36% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +285.36% | Nov 1, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +285.36% | Sep 13, 2023 |
Financial Forecast
Revenue This Year
612.00K
from 583.23K
Increased by 4.93%
Revenue Next Year
408.00K
from 612.00K
Decreased by -33.33%
EPS This Year
-2.62
from -3.95
EPS Next Year
-0.79
from -2.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 840,000 | 840,000 | 840,000 | 62.5M | 128.9M |
| Avg | 612,000 | 408,000 | 408,000 | 20.5M | 48.7M |
| Low | 392,000 | n/a | n/a | n/a | 8.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.0% | 37.3% | 105.9% | 15,225.0% | 530.3% |
| Avg | 4.9% | -33.3% | - | 4,912.5% | 138.1% |
| Low | -32.8% | - | - | - | -57.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.36 | -0.53 | -0.54 | -0.07 | 1.00 |
| Avg | -2.62 | -0.79 | -1.00 | -0.38 | 0.13 |
| Low | -2.83 | -1.03 | -1.43 | -0.67 | -0.68 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.